Indefinite Delivery Contract HHSN272201600004I

The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a single-award indefinite delivery contract to R T I International to provide preclinical services supporting the development of biopharmaceutical therapeutics and diagnostics for infectious diseases. With a potential value of $30 million over a seven-year ordering period from January 2023 to September 2030, this contract aims to procure services across five task areas: product development...

The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a single-award indefinite delivery contract to the University of Saskatchewan to provide preclinical services supporting the development of biopharmaceutical therapeutics and diagnostics for infectious diseases. With a potential value of $30 million over a seven-year ordering period from January 2023 to September 2030, this contract aims to procure services across five task areas: product...

The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded multiple indefinite delivery/indefinite quantity contracts to provide preclinical development support for candidate products and drug development activities ranging from initial product discovery to activities required for clinical trials and product licensure. Services will be conducted under seven task areas including in vitro testing, synthesis of therapeutic agents, small animal models for...

The National Institute of Allergy and Infectious Diseases awarded multiple indefinite delivery/indefinite quantity contracts to provide preclinical development support for candidate products and drug development activities ranging from initial product discovery to activities required for clinical trials and product licensure. The scope of work encompasses seven task areas: in vitro testing, synthesis of therapeutic agents, small animal models for HIV/HBV/HCV and mycobacterium, formulation...

The National Institute of Allergy and Infectious Diseases awarded a single-award Indefinite Delivery Indefinite Quantity contract to Pharm-Olam, LLC with a potential value of $30,000,000.00 to provide preclinical services supporting the development of biopharmaceutical therapeutics and diagnostics for infectious diseases. Services will be performed across five task areas: product development planning and evaluation; analytical assay development and product characterization; process development...

The National Institute of Allergy and Infectious Diseases awarded multiple Indefinite Delivery/Indefinite Quantity contracts to provide preclinical development support for candidate products and drug development activities ranging from initial discovery to clinical trials. Services are conducted under seven task areas including in vitro testing, synthesis of therapeutic agents, small animal models for HIV/HBV/HCV and mycobacterium, formulation development, preclinical pharmacology and...

The Department of Health and Human Services' National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) has awarded a single-award indefinite delivery contract to Polypeptide Laboratories San Diego, LLC, a Contract Development & Manufacturing Organization (CDMO), to provide chemistry, manufacturing, and controls (CMC) services for the development of drug substances. This five-year, $49.7 million IDV contract, awarded without set-asides, supports NCATS'...

The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a single award Indefinite Delivery Contract to Latham Biopharm Group, Inc. to provide preclinical services supporting the development of biopharmaceutical therapeutics and diagnostics for infectious diseases. With a potential value of $30 million and a period of performance from January 2023 through September 2030, the contract enables ordering under five task areas: product development planning and...

The Department of Health and Human Services Food and Drug Administration awarded an indefinite delivery contract to Propharma Group, LLC (doing business as Acadeus) with a potential value of $25 million. The contract provides review of Laboratory-Developed Tests and In Vitro Diagnostics Support through March 6, 2027. A $7.736 million firm fixed price delivery order was also awarded for the period of March 2, 2022 through September 6, 2024 in Silver Spring, Maryland. Under this delivery order,...

This indefinite delivery contract was awarded by a civilian federal agency to Labcorp Early Development Laboratories Inc., a subsidiary of Laboratory Corporation of America Holdings, to provide a range of laboratory testing and analytical services. The contract, which has a ceiling value of $2,530,101.01, is not set aside for small businesses. Through this contract, Labcorp Early Development Laboratories Inc. has performed stability testing, potency and safety assays, polyclonal antibody...